Nuvation Bio Inc
Company Profile
Business description
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Contact
1500 Broadway
Suite 1401
New YorkNY10036
USAT: +1 332 208-6102
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
307
Stocks News & Analysis
stocks
ASX utility share downgraded as electricity prices fall
stocks
Chart of the Week: AI market leader is now surprisingly cheap
stocks
Weekly earnings wrap: Rio Tinto leads the way
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,452.00 | 42.10 | 0.45% |
| CAC 40 | 8,736.07 | 66.78 | 0.77% |
| DAX 40 | 26,196.40 | 70.10 | 0.27% |
| Dow JONES (US) | 54,313.22 | 35.90 | -0.07% |
| FTSE 100 | 10,873.77 | 14.53 | -0.13% |
| HKSE | 25,530.28 | 385.54 | -1.49% |
| NASDAQ | 26,441.01 | 77.57 | 0.29% |
| Nikkei 225 | 65,683.26 | 617.18 | -0.93% |
| NZX 50 Index | 13,958.06 | 39.12 | -0.28% |
| S&P 500 | 7,738.96 | 15.41 | 0.20% |
| S&P/ASX 200 | 9,271.60 | 41.80 | 0.45% |
| SSE Composite Index | 3,900.35 | 21.92 | 0.57% |